| ABSTRACT Objective:To evaluate the short term therapeutic efficacy and safety of deproteinised calf serum injection adjuvant therapy of in patients with acute anterior circulation cerebral infarction. Methods:Ninety six patients with acute anterior circulation cerebral infarction were enrolled in the randomized single blind control trial. They were randomly divided into control group and treatment group, and 48 cases in each group. They were both treated by identical basis therapy, the control group received physiological saline, the treatment group received deproteinised calf serum injection additionally for 21 consecutive days. National Institute of Health Stroke Scale score (NIHSS), Barthel index (BI) and modified Rankin scale (mRS) were calculated to assess the neurological function impairment, activity of daily living and extent of disability in prognosis, respectively; the adverse reactions were recorded. Results:After 21 days’ treatment, the NIHSS score, mRS score, and BI score were siginificantly improved in both two groups(P<0.05). As compared with those in control group, the above indexs were significantly reduced in the treatment group (P<0.05). The clinical efficiency was 81.3% in the treatment group, which was higher than 62.5% of control group. No abnormal changes of blood routine examinations, rinalysis, hepatorenal function and ECG, no drug relative adverse reactions was noted either. Conclusion:The adjuvant therapy of deproteinised calf serum injection could improve the clinical outcomes of patients with acute anterior circulation cerebral infarction. |
